Skip to main content
SpringerLink
Log in

An expanding range of atypical antipsychotic agents to choose from

  • New Drugs and Therapeutic
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kerwin R, Taylor D. New antipsychotics. A review of their current status and clinical potential. CNS Drugs 1996 Jul; 6 (1)

  2. Higgins G. Future options for treating schizophrenia. Inpharma 1992 Jun 6; (840): 3–4

  3. Gerlach J, Peacock L. New antipsychotics: the present status. Int Clin Psychopharmacol 1995; 10 Suppl. 3: 39–48

    Article  PubMed  Google Scholar 

  4. Lieberman JA, Alvir JMJ. A report of clozapine-induced agranulocytosis in the US. Drug Saf 1992; 7 Suppl. 1: 1–2

    Article  PubMed  Google Scholar 

  5. Dunn CJ, Fitton A. Sertindole. CNS Drugs 1996 Mar; 5(3): 224–30

    Article  CAS  Google Scholar 

  6. Cunningham Owens DG. Adverse effects of antipsychotic agents. Do newer agents offer advantages? Drugs 1996 Jun; 51(6): 895–930

    Article  Google Scholar 

  7. Tran PV, Beasley CM, Tollefson GD, et al. Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent [abstract]. Neuropsychopharmacology 1994; 10 Suppl. 2: 267

    Google Scholar 

  8. Wood AJ, Beasley CM, Tollefson GD, et al. Efficacy of olanzapine on the positive and negative symptoms of schizophrenia [abstract]. Eur Neuropsychopharmacol 1994 Sep; 4(3): 224–5

    Article  CAS  Google Scholar 

  9. Link C, Smith A, Miller B, et al. A multicentre, double-blind, controlled comparison of Seroquel™ and chlorpromazine in the treatment of hospitalised patients with acute exacerbation of subchronic and chronic schizophrenia [abstract]. Eur Neuropsychopharmacol 1994 Sep; 4(3): 385

    Article  Google Scholar 

  10. Zborowkski J, Schmitz P, Staser J, et al. Efficacy and safety of sertindole in a trial of schizophrenic patients [abstract]. 148th Meeting of the American Psychiatric Association; 1995 May 20–25; Miami (FL).

  11. O’Connor R, Harrigan E, Heym J, et al. The efficacy and safety profile of a new antipsychotic, ziprasidone. Poster at the VIIIth Congress of the European College of Neuropsychopharmacology: 1995 Sep 30–Oct 4: Venice, Italy

  12. Schulz C, Staser J, Schmitz P, et al. An open-label assessment of the long-term safety of sertindole in the treatment of schizophrenic patients. Marcus Wallenberg Symposium on Schizophrenia; 1994 Sep; Gotherberg, Sweden.

  13. van Kammen DP, McEvoy JP, Targum SD. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996 Mar; 124: 168–75

    Article  PubMed  Google Scholar 

  14. Lundbeck first with new antipsychotic. Pharm J 1996 Jul 13; 257: 48

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

An expanding range of atypical antipsychotic agents to choose from. Drugs Ther. Perspect 8, 1–5 (1996). https://doi.org/10.2165/00042310-199608030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199608030-00001

Search

Navigation